Company: AGIO
Filing Date: 2025-02-13
Form Type: 10-K
Source: 0001439222-25-000009
Chunk: 854

Company: AGIOS PHARMACEUTICALS, INC.
Filing Date: 2025-02-13
Form: 10-K
Item: Item 12
Chunk 854
---
43.48 6.21$11,911 The weighted-average grant date fair value of options granted was $18.92, $14.32 and $15.64 during the years ended December 31, 2024, 2023 and 2022, respectively. The total intrinsic value of options exercised was $3.3 million, $2.9 million and $0.3 million during the years ended December 31, 2024, 2023 and 2022, respectively.At December 31, 2024, the total unrecognized compensation expense related to unvested stock option awards was $29.1 million, which we expect to recognize over a weighted-average period of approximately 2.37 years.Restricted stock unitsUpon vesting, each RSU entitles the holder to receive a specified number of shares of our common stock. The following table presents RSU activity for the year ended December 31, 2024:Number ofStock UnitsWeighted-AverageGrant DateFair ValueUnvested shares at December 31, 20231,346,701 $29.67 Granted1,144,164 32.33 Vested(594,511)32.70 Forfeited(77,791)30.86 Unvested shares at December 31, 20241,818,563 $30.31 As of December 31, 2024, there was approximately $33.6 million of total unrecognized compensation expense related to RSUs, which we expect to be recognized over a weighted-average period of 1.87 years.Performance-based stock unitsAt the achievement of the performance-based and service-based vesting criteria, each PSU entitles the holder to receive a specified number of shares of our common stock. The following table presents PSU activity for the year ended December 31, 2024:Number ofStock UnitsWeighted-AverageGrant DateFair ValueUnvested shares at December 31, 2023362,133 $30.66 Granted183,000 32.27 Vested(170,550)35.04 Unvested shares at December 31, 2024374,583 $29.45 Stock-based compensation expense associated with these PSUs is recognized if the underlying performance condition is considered probable of achievement using our management’s best estimates. As of December 31, 2024, there was no unrecognized compensation expense related